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Abstract
Background: Fever is one of the most commonly observed abnormal signs in patients with critical illness.
However, there is a paucity of evidence to guide the management of febrile patients without acute brain injury
and little is known about the biologic response to treatment of fever. As such, observational studies suggest that
the treatment of fever is inconsistent. This pilot clinical trial will assess the safety and feasibility of treating febrile
critically ill adult patients with an aggressive versus a permissive temperature control strategy. The biologic
response to these two different temperature control strategies will also be assessed through analysis of a panel of
inflammatory mediators.
Findings: The study population will include febrile adult patients admitted to one of two general medical-surgical
intensive care units (ICUs) in Calgary, Alberta, Canada. Patients will be randomized to either an aggressive or
permissive fever treatment strategy. The aggressive group will receive acetaminophen 650 mg enterally every 6
hours upon reaching a temperature ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C,
whereas the permissive group will receive acetaminophen 650 mg every 6 hours upon reaching a temperature ≥
40.0°C and external cooling for temperatures ≥ 40.5°C. The study will take place over 12 months with the goal of
enrolling 120 patients. The primary outcome will be 28-day mortality after study enrolment, with secondary
outcomes that will include markers of feasibility (e.g. the enrolment rate, and the number of protocol violations),
and levels of select inflammatory and anti-inflammatory mediators.
Discussion: Results from this study will lead to a better understanding of the inflammatory effects of anti-pyretic
therapy and will evaluate the feasibility of a future clinical trial to establish the best treatment of fever observed in
nearly one half of patients admitted to adult ICUs.
Trial Registration: ClinicalTrials.gov: NCT01173367
Background
Fever, an adaptive response to physiologic stress, is one
of the most commonly observed abnormal signs in
patients with critical illness, occurring in almost 50% of
patients admitted to intensive care units (ICUs) [1-3].
Fever has also been shown to be independently asso-
ciated with mortality in patients admitted to ICUs [1,4].
In spite of this, there is a lack of robust data to guide the
management of pyrexia. This frequently leaves the deci-
sion to treat elevated body temperature at the discretion
of the bedside nurse [5,6]. This decision is further com-
plicated by the contradictory nature of the current avail-
able molecular data regarding the initiation and
progression of fever, which leads to difficulties in know-
ing which pathways may be involved and therefore which
temperature lowering strategy should be employed.
A core body temperature ≥ 38.3°C is generally accepted
to represent fever which may occur as a result of a num-
ber of infectious and non-infectious etiologies [3]. The
gold standard for measuring core temperature is the ther-
mistor on a pulmonary-artery catheter (PAC). Similarly
accurate temperature recordings can be obtained from
urinary bladder catheter thermistors, esophageal probes,
and rectal thermometers [7]. However, these methods of
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and invasive to use on all critically ill patients. Therefore
the temperature of many ICU patients is assessed using
more cost-effective, less invasive, albeit less accurate
devices such as the infrared tympanic membrane and
temporal artery thermometers [3].
Few studies have reported on the epidemiology of fever
in general medical and surgical ICU patients [1,4,8,9].
Circiumaru and colleagues found that prolonged fever
was associated with increased mortality (62.5% versus
29.6%, p < 0.0001), however this was not adjusted for ill-
ness severity, etiology or other potential confounders [8].
Peres Bota et al found that fever occurred in 139 of 493
adult patients admitted to their tertiary care ICU (28.2%)
[9]. Fever was commonly present at ICU admission
(76.3%) and was frequently infectious in origin (55%).
Febrile patients had significantly increased mortality
compared to patients with normothermia (35.3% versus
10.3%, p < 0.01), however this was not adjusted for
potential confounders. Barie and colleagues also found
fever to occur among 26% of 2,419 patients admitted to
their surgical ICU [4]. Patients with fever had an
increased overall mortality compared to the afebrile
cohort (26.5% versus 6.5%, p < 0.0001) and peak tem-
perature was independently associated with mortality
(odds ratio (OR) 1.84 for each one-degree increase in
temperature, 95% confidence interval (CI) 1.23 - 2.75). In
the largest study looking at the epidemiology of fever in
general medical and surgical ICU patients, Laupland et al
found that the cumulative incidence of fever was 44%
among 20,466 patients admitted to ICUs in Calgary,
Alberta, Canada between 2000-2006 [10]. Compared to
medical patients that did not develop a fever during ICU
admission, medical patients who were afebrile at ICU
admission and subsequently went on to develop high
fever were at increased risk of death (adjusted OR1.91,
95% CI 1.36 - 2.70). The reasons for this increased risk of
death are unclear, but may arise from enhanced under-
standing of the effects of treating or not treating fever on
the pathways involved in propagating or abrogating fever.
The production of fever involves a complex series of
reactions between exogenous and endogenous pyrogens.
Knowledge of these mechanisms is important as it will
help to guide clinical decisions regarding the manage-
ment of patients with pyrexia. The most cited mechanism
for the induction of infectious fever is derived from a
lipopolysaccharide (LPS) model of Gram-negative bacter-
ial sepsis. In this model, LPS travels to the liver Kupffer
cell which results in the production of the complement
component C5a [11,12]. C5a promotes the release of
prostaglandins (PGE2) from these cells, which transmits
the message via the vagus nerve to the nucleus tractus
solitarius in the brainstem [11,13,14]. The signal then tra-
vels to the hypothalamus and triggers both an early and a
delayed rise in temperature. The early temperature rise is
a result of the depression of the firing of warm-sensitive
neurons via an a1-adreno receptor (AR), PGE2-indepen-
dent pathway [15]. Clinically, this correlates with chills
and rigors [16]. The delayed temperature rise starts with
an interaction between norepinephrine and an a2-AR
t h a tr e s u l t si na ni n c r e a s ei nP G E 2 production via the
cyclooxygenase-2 enzyme (COX-2) [15]. This is asso-
ciated with a more prolonged rise in core temperature
than that of the PGE2-independent pathway and is
responsible for the persistence of fever in the face of an
infectious stimulus.
This delayed pathway is also the site of action of anti-
pyretics such as acetaminophen [13,17]. The effect of
temperature lowering agents on the levels of many
endogenous inflammatory (e.g. interleukin (IL)-1b,I L - 6 ,
and tumour necrosis factor (TNF)-a) and anti-inflam-
matory molecules (e.g. IL-1 receptor antagonist (IL-1
RA), IL-10, and TNFa-binding protein (TNFa-BP)) is
unclear. Knowledge of the biologic consequences of
fever management is important because excessively ele-
vated temperatures are associated with adverse cellular
effects yet strategies that lower temperature may impair
the ability of the host to clear an infection.
Unfortunately, there is a paucity of evidence to guide the
treatment of fever in critically ill patients and strong argu-
ments exist to justify treating and not treating elevated
body temperatures. Studies arguing against temperature
lowering strategies have shown that naturally hypothermic
septic patients are at higher risk for death than patients
who are able to generate a fever [8,9,18,19]. In addition,
commonly employed anti-pyretics (non-steroidal anti-
inflammatories (NSAIDs), and/or acetaminophen) are
associated with a not insignificant risk of bleeding, and
hepatic and renal toxicity [20]. Treatment of fever may
also mask the presentation and diagnosis of severe under-
lying infections. This in turn may delay administration of
appropriate antimicrobial therapy which is clearly asso-
ciated with increased mortality [21,22]. On the other hand,
temperatures sustained at extremely high levels (> 40°C)
may worsen cerebral edema and precipitate multisystem
organ failure [23]. It is generally accepted that these
extreme temperatures be lowered using pharmacologic
and/or external cooling methods. However there is no
consensus opinion with regard to the management of
patients whose temperature is between 38.3°C and 40.0°C.
There are relatively few randomized trials that assess
the effects of anti-pyretic therapy on critically ill adults
without acute neurological injury. With the exception of
one trial [24], most of these studies are limited by small
sample size [25-28] or an inability to perform a true
randomization of interventions [27]. Bernard et al ran-
domized 455 septic patients with fever or hypothermia
and at least one organ failure to receive either 10 mg/kg
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[24]. Unfortunately there was no difference in the pri-
mary outcome of 30-day mortality (37% for ibuprofen
versus 40% for placebo); however this may have been
due to a bias introduced by the differential use of aceta-
minophen within the intervention and placebo groups
respectively. Gozzoli et al randomly assigned 38 febrile
patients with systemic inflammatory response syndrome
(SIRS) admitted to their surgical ICU to receive either
external cooling or no anti-pyretic therapy for a tem-
perature ≥ 38.5°C [26]. This study also did not show an
appreciable difference in any clinically significant
outcome.
Finally, Schulman et al randomized 82 febrile patients
admitted to a surgical ICU to receive either an aggressive
or permissive temperature management strategy [25].
The aggressive treatment group received acetaminophen
650 mg every 6 hours when their temperature was above
38.5°C and a cooling blanket was added if the tempera-
ture exceeded 39.5°C. The permissive treatment group
did not receive treatment until their temperature
exceeded 40.0°C at which point this group received the
aggressive treatment protocol. This study was stopped
early due to a trend towards an increased number of
deaths in the aggressive group (seven versus one in the
permissive group, p = 0.06). This may have been due to
several factors, including the fact that patients required
an antecedent ICU length of stay of 72 hours to be
included in the study. This may have selected for patients
with more severe nosocomial illnesses such as nosoco-
mial pneumonia and bloodstream infection. These
authors also did not report the proportion of patients
who experienced cooling blanket intolerances and how
this was managed (i.e. use of sedatives, neuromuscular
blockers, or meperidine). An increased use of these drugs
may help to explain the increased mortality observed in
the aggressive fever treatment group. Finally, this study
was not designed to detect a difference in mortality and
this unexpected finding needs to be confirmed in a larger
trial.
Given the lack of robust data to guide the management
of temperature among febrile ICU patients, treatment
with anti-pyretic agents is inconsistent. This is supported
by the results of two studies that retrospectively looked
at anti-pyretic prescribing practices in hospitalized
patients [5,6]. Isaacs and colleagues found that 50% of
patients admitted to their academic institution between
1986 - 1987 received an anti-pyretic order and 86% of
anti-pyretic orders were written to be given “as needed”
at the discretion of the bedsi d en u r s e .M o r er e c e n t l y ,w e
found that 79 of 100 non-neurologically injured febrile
critically ill adults received pharmacologic and/or physi-
cal anti-pyretic therapy. Few patients receiving this ther-
apy had an explicit order to guide this management strat-
egy (5/79). Though these two publications are separated
by more than 20 years, the results are very similar and
suggest that inconsistencies in fever management are
likely the standard of care.
As it is unclear how to approach fever in the general
ICU patient without acute brain injury (neurologically
intact) or acute myocardial infarction, this pilot, rando-
mized clinical trial will assess the safety and feasibility of
treating febrile critically ill patients with an aggressive as
compared to a permissive temperature management
strategy. This study will also examine the effect of anti-
pyretic therapy on consumption of anti-microbials, and
the incidence of nosocomial infection, as well as the
effect of anti-pyretic treatment of fever on markers of
inflammation. This may lead to a better understanding
of the inflammatory effects of anti-pyretic therapy and
will lay the groundwork for a future clinical trial that
may be expected to have a major influence on the treat-
ment of nearly one half of patients admitted to adult
ICUs.
Methods
Study design and participants
This will be a parallel, randomized clinical trial with 1:1
group allocation to either an aggressive or permissive fever
treatment strategy. For the purposes of this study, the
term fever treatment will refer to the use of anti-pyretic
medications and/or physical cooling, whereas the term
fever management will refer to the selection of appropriate
investigations, the use of anti-microbials, and anti-pyretic
therapies. The study protocol has been approved by the
Conjoint Health Research Ethics Board (CHREB) at the
University of Calgary and is registered (http://Clinical-
trials.gov identifier NCT01173367). The recruitment of
study participants will take place in the Peter Lougheed
Centre (PLC) ICU and the Foothills Medical Centre
(FMC) ICU. The PLC ICU is a 16-bed multi-system ICU
that admits a wide range of medical and surgical patients
and is the non-cardiac vascular surgery referral centre for
southern Alberta. The FMC ICU is a 25-bed unit that
serves as the regional trauma and neurosurgical referral
center, but also admits a wide range of medical and surgi-
cal patients. Eligibility criteria will be:
Inclusion Criteria
￿ Age ≥ 18 years old
￿ Fever (two consecutive measurements ≥ 38.3°C at
least 2 hours apart or a single temperature measure-
ment ≥ 39.5°C)
￿ Admission to ICU with an expected length-of-stay
≥ 48 hours
￿ Attending physician approval
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￿ Admission to ICU for support for a specific proce-
dure (e.g. endoscopy, acute dialysis, bronchoscopy)
￿ Acute brain injury due to any etiology
￿ Acute myocardial ischemia
￿ Documented hepatitis (alanine aminotransferase
[ALT] more than twice the upper limit of normal),
or chronic hepatic failure (defined by evidence of
cirrhosis on available imaging or known varices,
ascites, hepatic encephalopathy, hepatorenal syn-
drome, and/or hepatocellular carcinoma)
￿ Hyperthermia syndromes (malignant hyperthermia,
heat stroke, neuroleptic malignant syndrome, seroto-
nin syndrome, or endocrine causes including thyro-
toxicosis, pheochromocytoma, and adrenal crisis)
￿ Refractory shock with lactic acidosis > 4 mmol/L
(at the time of screening for study enrolment)
despite supportive therapy
￿ Requirement for use of acetaminophen or non-
steroidal anti-inflammatory drugs for indications
other than treatment of fever
￿ Receipt of anti-pyretic pharmacotherapy within
6-hours of expected study enrolment (650 mg aceta-
minophen, 800 mg ibuprofen, or 325 mg acetylsa-
licylic acid)
￿ Contraindications to esophageal temperature
monitoring
￿ Pregnancy (all women of child-bearing potential
will have a pregnancy test performed)
￿ Time from onset of fever in the ICU to study
enrolment > 12 hours (due to the need to assess the
timing of expression of various inflammatory
mediators)
Given the time constraints associated with timely
measurement of inflammatory markers, the CHREB
approved a waiver of initial consent for enrolment into
this study. As such, if the patient or their SDM is not
available to discuss consent, the patient will be enrolled
into the study and consent obtained subsequent to
initiation of the study protocol. The goal will be to
obtain formal consent within 24-hours of study enrol-
ment. If consent is unable to be obtained within
24-hours after enrolment, the patient will be excluded
from further study participation. Patients and their SDM
will be able to withdraw consent at any point during the
study.
Randomization and blinding
The randomization scheme will be developed using the
technique of simple block randomization. This scheme
will be generated and maintained by one of the co-prin-
cipal investigators not directly involved with patient
enrolment (H.T.S.). Allocation will be concealed using
the consecutively, numbered, sealed opaque envelope
technique. As such it will not be possible for the treat-
ing clinicians, or other study investigators to know the
treatment group assignment prior to randomization.
Envelopes will not be opened until the patient’sn a m ei s
recorded in the study log.
Due to cost and logistic constraints, patients, nurses,
and the attending ICU team will not be blinded to study
treatment assignment. However, lab personnel will be
blinded to study group assignment, and all safety out-
comes will be objectively reviewed in a blinded fashion
by two intensivists not involved with patient enrolment.
Temperature management protocol
The initial temperature measurement that meets febrile
criteria will be obtained by the temporal artery method.
Recent data has shown that temporal artery thermo-
meters become inaccurate (by nearly 1°C) at the
extremes of temperature [29]. Other more accurate, but
somewhat invasive methods of temperature measure-
ment include continuous bladder, esophageal, and rectal
thermometers. As it will not be feasible to monitor all
ICU patients with one of these continuous temperature
monitors, the temporal artery method is a more cost-
effective means of identifying patients for this study.
Once a patient is enrolled in this study, their core tem-
perature will be monitored using a continuous esopha-
geal temperature probe until resolution of fever (defined
as no fever for 3 consecutive days) or removal of their
endotracheal tube.
Patients that meet enrolment criteria will be randomly
allocated to the permissive or aggressive fever treatment
group. Study patients will remain in their assigned
group for the duration of their stay in the ICU. Patients
assigned to the aggressive fever treatment protocol will
receive acetaminophen 650 mg enterally every 6 hours
for a temperature ≥ 38.3°C and external cooling will be
initiated for temperatures ≥ 39.5°C. External cooling will
consist of cool face cloths, ice packs, room fans, and a
decrease in the ambient room temperature. Cooling
blankets will be added at the discretion of the attending
physician. Acetaminophen and external cooling will be
discontinued once core temperature is less than 38.3°C
and 39.5°C respectively. Patients assigned to the permis-
sive treatment strategy will not receive anti-pyretic ther-
apy until their temperature reaches 40.0°C at which
point they will receive acetaminophen 650 mg every 6
hours. External cooling will be initiated for temperatures
≥ 40.5°C (as per interventions listed for aggressive
group). Similar to the aggressive group, acetaminophen
and external cooling will be discontinued once core
temperature is less than 40.0°C and 40.5°C respectively.
I fa ta n yt i m ed u r i n gt h i ss t u d y ,ap a t i e n t ’s temperature
reaches 41.0°C, regardless of group assignment, the
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attending physician until core body temperature is less
than 40.5°C, at which point they will be managed
according to that of their respective treatment arm. If at
any point a patient, SDM or attending physician decides
that ongoing participation in the study is not in the
patient’s best interest, the patient may be removed from
the study.
Laboratory studies
The plasma levels of 19 mediators relevant to inflamma-
tory and/or pyrexia mechanisms will be examined
(Table 1). Plasma will be isolated upon study admission
and at 12, 24, and 48-hours after the start of the treat-
ment. Venous or arterial blood will be collected from an
existing intravascular line into a BD citrated plasma
tube, gently inverted several times and centrifuged at
1700 × g for 10 minutes at 4°C. The plasma will then be
collected, taking all necessary measures not to disturb
the pellet, and aliquoted (250 ul each) into appropriately
labelled cryopreservation tubes. The aliquots will be
stored at -80°C until further analysis.
The levels of the inflammatory mediators outlined in
Table 1 will be determined by either Luminex technol-
ogy or an enzyme-linked immunosorbent assay (ELISA).
The Luminex equipment allows for measurement of
several analytes at the same time using the x-MAP
technology. This technique combines the specificity and
reproducibility of the ELISA technique with the multi-
plexing capacity of the fluorescent-bead immunoassays,
thus maximizing the utilization of the sample. Indeed,
this technique requires as little as 100 μl total of plasma
per patient for all the mediators described below. This
technique is relatively novel but has been fully validated
[44]. Furthermore, this multiplexing technology mini-
mizes both the inter-assay variability and the time and
cost required to perform these measurements. Finally,
Bio-Plex Manager Software version 6.0 will be used for
the analysis of the results as it automatically draws the
standard curves and infers the concentration of each
samples, limiting the possibility of human errors.
Two panels of commercially available antibody coupled
beads will be selected to detect the following mediators.
Panel A will be used to measure IL-1b, IL-1RA, Il-4, IL-8,
IL-10, IL-17, IFN-g,T N F - a, IL-6, RANTES, MIP-1a,
sTNF-RI and sTNF-RII, while panel B will be used to
measure IL-18, GRO-a and TRAIL. Two panels are
required due to buffer incompatibilities. Each of these
panels will be assayed following the manufacturer’s
instructions and read using a Luminex 200 instrument
(Luminex, Texas, USA). The data will be analyzed using
Bio-Plex Manager Software version 6.0.
As there is no commercially available Luminex-compa-
tible bead to measure HSP60, HSP70 and HSP90 these
mediators will be measured by a standard commercially
available ELISA kit. Each mediator will be analyzed
Table 1 Inflammatory mediators of interest
Mediator Role in Pyrexia or Inflammation Reference
IL-1b Potent endogenous pyrogen [30]
IL-1RA Endogenous anti-pyretic cytokine [31]
Il-4 Key mediator of humoral and adaptive immunity [32]
IL-6 Potent pro-inflammatory cytokine and pyrogen [30]
IL-8 Neutrophil chemotactic factor [33]
IL-10 Endogenous anti-pyretic cytokine [34]
IL-17 Potent pro-inflammatory mediator [35]
IL-18 Amplifies the innate immune response [36]
IFN-g Endogenous pyrogen [30]
TNF-a Endogenous pyrogen and ubiquitous inflammatory mediator [37]
RANTES Chemotactic factor for T-cells, dendritic cells, and NK cells [38]
MIP-1a Leukocyte chemotactic factor [39]
GRO-a Neutrophil chemotactic factor [40]
TRAIL Involved in inducing cellular apoptosis [41]
sTNF-RI Involved in mediating the apoptotic effects of TNF-a [42]
sTNF-RII Involved in modulating T-cell proliferation [42]
HSPs (60, 70, 90) Mediators of an adaptive response to cellular stress [43]
Abbreviations: IL-1b, interleukin-1b; IL-1RA, interleukin-1 receptor antagonist; IL-4, interleukin-4; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; IL-17,
interleukin-17; IL-18, interleukin 18; IFN- g, interferon- g; TNF-a, tumor necrosis factor-a; RANTES, Regulated upon Activation, Normal T-cell Expressed, and
Secreted; MIP-1a, macrophage inflammatory protein-1a; GRO-a, growth-related oncogene-a; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; sTNF-
R1, soluble tumor necrosis factor-a receptor-I; sTNF-RII, soluble tumor necrosis factor-a receptor-II; HSPs, heat shock proteins; NK, natural killer
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kit. The data will be acquired using a PerkinElmer Victor
X4 plate reader and analyzed with the WorkOut 2.5
software.
Outcome Measures and Data Collection
Clinical data will be recorded from the time of enrol-
ment until day 28 following enrolment and will be pri-
marily obtained from the hospital electronic medical
record (Quantitative Sentinel, GE-Marquette Medical
Systems Inc. Milwaukee, WI, USA; Sunrise Clinical
Manager version 5.7, Eclipsys Corporation; Web-based
diagnostic imaging system, Agfa WEB1000 version 4.1
SP3) as previously described [1]. Survival at day 28 will
be established by phone call follow-up for those patients
discharged prior to this date. Patients will be followed
for evidence of new nosocomial infection and these will
be classified using standard Centres for Disease Preven-
tion and Control criteria.
As this study is concerned with the safety and feasibility
of the aforementioned temperature control regimen, the
primary outcome will be mortality 28-days after study
enrolment. Secondary outcomes of interest include mar-
kers of feasibility (i.e. enrolment rate [number of patients
enrolled/number of eligible candidates], adherence of
patients to assigned treatment regimen, and acceptance of
the protocol by staff) and other markers of safety (nosoco-
mial infection rate, evidence of myocardial ischemia, and/
or hepatocellular inflammation). Other secondary out-
comes include the total number of days of anti-microbials
used, number of microbiologic and radiologic tests, and
changes in the levels of the previously mentioned inflam-
matory mediators.
Statistical analyses
All statistical analyses will be performed using Stata ver-
sion 11.2 (Stata Corp, College Station, TX). Data will be
analyzed according to the intention-to-treat method. Prior
to description or statistical testing, all continuous variables
will be asssessed for underlying distribution using histo-
grams. Normally distributed variables will be reported as
means ± standard deviations (SD) and skewed variables as
medians with inter-quartile ranges (IQR). Mean and med-
ian values for clinical data will be compared using the
Student’s t-test or the K-sample equality of medians test.
Similarly, differences in proportions among categorical
data will be assessed using Fisher’s exact test for pair-wise
comparisons and the chi
2 test for multiple groups. The
unadjusted primary outcome of 28-day mortality will be
analyzed using Fisher’s exact test. Logistic regression will
be employed to provide an adjusted estimate of the odds
of 28-day mortality. A priori defined variables to incorpo-
rate into this model include APACHE II score, admission
diagnostic classification, and whether the fever is
infectious in etiology. Other variables to include in the
model will be those associated with a p-value ≤ 0.1 in the
univariate analyses. Differences in the levels of the afore-
mentioned panel of inflammatory mediators will be ana-
lyzed using univariate statistics appropriate for dependent
data, namely a paired t-test for data with a normal distri-
bution, or the Wilcoxon signed rank test for skewed data.
As this is a pilot study, a formal sample size calculation
was not performed. However, an estimate of the pro-
jected recruitment over one-year was calculated based on
previous work in this study’s health region [1]. In the pre-
viously described study by Laupland et al, 5,753 patients
were found to have fever among all patients admitted to
four ICUs in the Calgary Health Region from 2000 -
2006 [1]. The PLC ICU and FMC ICU comprise roughly
63% of those ICU beds. This translates into an approxi-
mate 3,624 febrile patients over the seven years of that
study, which equates to 43 patients per month with fever.
Using a conservative estimate of capturing 25% of all
potentially eligible patients, this study is expected to
enroll 10 patients per month which will result in a total
of 120 patients at the end of one year of recruitment. As
this is a pilot study, the authors feel that this is an ade-
quate number of patients to evaluate the safety and feasi-
bility outcomes of interest. Thus the enrolment phase of
this study is projected to require one-year.
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